The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Efficacy of post-lenvatinib treatments in patients (pts) with advanced renal cell carcinoma (aRCC).
 
Justine Panian
No Relationships to Disclose
 
Caiwei Zhong
No Relationships to Disclose
 
Sharon Choi
No Relationships to Disclose
 
Roxanne Quinn
No Relationships to Disclose
 
Evan Ferrier
No Relationships to Disclose
 
Eddy Saad
No Relationships to Disclose
 
Renee Maria Saliby
No Relationships to Disclose
 
Carmel Malvar
No Relationships to Disclose
 
Sumanta Kumar Pal
Travel, Accommodations, Expenses - crispr therapeutics; Exelixis; Ipsen
 
Hedyeh Ebrahimi
No Relationships to Disclose
 
Ben Tran
Honoraria - Amgen; Astellas Pharma; Bayer; Bristol-Myers Squibb; Janssen; Janssen-Cilag; Pfizer; Sanofi; Tolmar
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Ipsen; IQvia; Janssen-Cilag; MSD Oncology; Novartis; Pfizer/EMD Serono; Pfizer/EMD Serono; Roche Molecular Diagnostics; Sanofi; Tolmar
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb; Genentech (Inst); Ipsen; Janssen-Cilag (Inst); Merck Sharp & Dohme; Pfizer (Inst)
Travel, Accommodations, Expenses - Amgen; Astellas Pharma
 
Andrew James Weickhardt
Honoraria - Eisai; Merck Sharp & Dohme
Consulting or Advisory Role - Bristol-Myers Squibb; Merck Sharp & Dohme; Pfizer; Telix Pharmaceuticals
Speakers' Bureau - Astellas Pharma
Research Funding - Merck
Travel, Accommodations, Expenses - Astellas Pharma; Ipsen; Merck Sharp & Dohme
 
Aly-Khan A. Lalani
Honoraria - Astellas Pharma; Bayer; Bristol-Myers Squibb; Eisai; Ipsen; Merck; Novartis; Pfizer; Roche/Genentech
Consulting or Advisory Role - Abbvie; Astellas Pharma; Bayer; Bristol-Myers Squibb; Eisai; Ipsen; Janssen; Merck; Novartis; Pfizer
Research Funding - BioCanRx (Inst); Bristol-Myers Squibb (Inst); EMD Serono (Inst); Ipsen (Inst); Novartis (Inst); Roche (Inst)
 
Cristina Suárez
Consulting or Advisory Role - Astellas Pharma; Bristol-Myers Squibb; Eisai; EUSA Pharma; Ipsen; Merck Sharp & Dohme; Pfizer; Roche/Genentech (Inst)
Speakers' Bureau - Bristol-Myers Squibb; Eisai; Ipsen; Merck Sharp & Dohme; Pfizer; Roche/Genentech
Research Funding - AB Science (Inst); Aragon Pharmaceuticals (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst); Sanofi Aventis GmbH (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Ipsen; Roche
 
Guillermo de Velasco
Honoraria - Astellas Pharma; BMS; Ipsen; Pfizer
Consulting or Advisory Role - Astellas Medivation; Bayer; Bristol-Myers Squibb; Ipsen; Merck; MSD; Novartis; Pfizer; Pierre Fabre; Pierre Fabre; Roche
Research Funding - Ipsen
Travel, Accommodations, Expenses - BMS; BMS; Roche
 
Ravindran Kanesvaran
Honoraria - Astellas Pharma; Bristol-Myers Squibb; Ipsen; Janssen; Merck; MSD Oncology; Novartis
Consulting or Advisory Role - Arcus Biosciences; Astellas Pharma; Janssen Oncology; MSD Oncology; Novartis; pfizer
Research Funding - Janssen (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; MSD Oncology
 
Martin Zarba
No Relationships to Disclose
 
Toni K. CHOUEIRI
Stock and Other Ownership Interests - Curesponse; Inndura; Osel; Pionyr; Precede Bio; Primium; Tempest Therapeutics
Honoraria - Alkermes; Analysis Group; Aravive; Arcus Biosciences; Arcus Biosciences; ASCO; AstraZeneca; Bayer; Bristol-Myers Squibb; Clinical Care Options; Eisai; EMD Serono; ESMO; Exelixis; Foundation Medicine; Gilead Sciences; Gilead Sciences; GlaxoSmithKline; Harborside Press; HiberCell; Infinity Pharmaceuticals; Ipsen; Janssen Oncology; Kanaph Therapeutics; Lancet Oncology; Lilly; Merck; Michael J. Hennessy Associates; Navinata Health; NCCN; NiKang Therapeutics; Novartis; Peloton Therapeutics; Pfizer; PlatformQ Health; Precede Bio; Prometheus; Roche/Genentech; Sanofi/Aventis; Scholar Rock; Tempest Therapeutics; The New England Journal of Medicine; UpToDate
Consulting or Advisory Role - alkermes; Analysis Group; Aravive; Arcus Biosciences; ASCO; AstraZeneca; Bayer; Bristol-Myers Squibb; Clinical Care Options; Eisai; EMD Serono; ESMO; Exelixis; Foundation Medicine; Gilead Sciences; Gilead Sciences; GlaxoSmithKline; Harborside Press; Infinity Pharmaceuticals; Ipsen; Janssen Oncology; Kanaph Therapeutics; Lancet Oncology; Lilly; Merck; Michael J. Hennessy Associates; Navinata Health; NCCN; Neomorph; NiKang Therapeutics; Novartis; Peloton Therapeutics; Pfizer; PlatformQ Health; Precede Bio; Prometheus; Roche/Genentech; Sanofi/Aventis; Scholar Rock; Tempest Therapeutics; The New England Journal of Medicine; UpToDate
Research Funding - Agensys (Inst); Arcus Biosciences (Inst); AstraZeneca (Inst); AVEO (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Eisai (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); Ipsen (Inst); Merck (Inst); NiKang Therapeutics (Inst); Novartis (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Roche (Inst); Roche/Genentech (Inst); Seattle Genetics/Astellas (Inst); Takeda (Inst); TRACON Pharma (Inst)
Patents, Royalties, Other Intellectual Property - -International Patent Application No. PCT/US2018/058430, entitled “Biomarkers of Clinical Response and Benefit to Immune Checkpoint Inhibitor Therapy (Inst); ctDNA technologies; International Patent Application No. PCT/US2018/12209, entitled “PBRM1 Biomarkers Predictive of Anti-Immune Checkpoint Response (Inst)
Travel, Accommodations, Expenses - Alexion Pharmaceuticals; alligent; Analysis Group; AstraZeneca; Bayer; Bristol-Myers Squibb; Cerulean Pharma; Clinical Care Options; Corvus Pharmaceuticals; Eisai; EMD Serono; ESMO; Exelixis; Foundation Medicine; GlaxoSmithKline; Harborside Press; HERON; Ipsen; Kidney Cancer Association; Lancet Oncology; Lilly; Lpath; Merck; Michael J. Hennessy Associates; Navinata Health; NCCN; Novartis; Peloton Therapeutics; Pfizer; PlatformQ Health; Prometheus; Roche/Genentech; Sanofi/Aventis; The New England Journal of Medicine; UpToDate
Other Relationship - Medical writing and editorial assistance support may have been funded by Communications companies funded by pharmaceutical companies such as ClinicalThinking, Health Interactions, Envision Pharma Group, Fishawack Group of Companies, Parexel
 
Daniel Yick Chin Heng
Consulting or Advisory Role - Astellas Pharma; Bristol-Myers Squibb; Eisai; Ipsen; Janssen; Merck; Novartis; Pfizer
Research Funding - Bristol-Myers Squibb (Inst); Exelixis (Inst); Ipsen (Inst); Novartis (Inst); Pfizer (Inst)
 
Rana R. McKay
Consulting or Advisory Role - Ambrx; Ambrx; Arcus Biosciences; Astellas Medivation; AstraZeneca; AVEO; Bayer; Blue Earth Diagnostics; Bristol-Myers Squibb; Calithera Biosciences; Caris Life Sciences; Dendreon; Esiai; Exelixis; Janssen; Lilly; Merck; Myovant Sciences; Novartis; Pfizer; Sanofi; Seagen; Sorrento Therapeutics; Sumitomo Pharma Oncology; Telix Pharmaceuticals; Tempus; Vividion Therapeutics
Research Funding - Artera (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol Myers Squibb (Inst); Exelixis (Inst); Oncternal Therapeutics (Inst); Tempus (Inst)